May 22, 2026
A competitor files a BLA for an asset you thought was two years behind yours. A PBM announces formulary exclusions hitting your lead product's category. A large-cap acquirer closes a bolt-on in your exact therapeutic space — the one you were positioning to enter. You find out when the press release drops.
That is not bad luck. It is the predictable result of treating competitive intelligence as a secondary function rather than a core strategic input.
In biopharma, CI tends to attract serious investment only after a company has already been surprised. That sequence — underinvest, get caught off guard, respond — is almost entirely preventable. This article examines why the underinvestment happens, what it costs, and what a properly resourced CI function actually looks like.
The Pattern Is Predictable — and Expensive
Most biopharma organizations have some form of CI. They track FDA approvals, monitor clinical trial registries, and read the same industry publications their competitors read. What they typically lack is a function capable of synthesizing signals across regulatory, commercial, payer, and BD&L dimensions in real time — and translating that synthesis into decisions.
The gap between "we monitor the space" and "we understand what is about to happen in our space" is where companies lose material ground. A phase II readout from a competitor does not just affect clinical strategy. It affects your partnership valuation, your formulary negotiating position, your investor narrative, and your BD pipeline — simultaneously. Companies that process these signals in isolation, or process them slowly, are operating on point-in-time intelligence in a market that has already moved.
What CI Actually Means in a Biopharma Context
Competitive intelligence in biopharma is not a database subscription. It is not a quarterly report from a third-party analyst. Those inputs have value, but they are inputs — not a CI function.
A genuine CI capability integrates pipeline tracking, regulatory intelligence, payer landscape monitoring, and BD activity into a continuous picture of competitive positioning. It answers questions like: Which competitors are within 18 months of LOE on assets adjacent to yours? Which PBMs are signaling formulary restructuring in your therapeutic category? Which acquirers have publicly stated appetite for assets in your indication — and what have they actually paid in the last 24 months?
These are not research questions. They are strategic questions that require ongoing synthesis, not periodic snapshots. The distinction matters because the commercial implications of a missed signal compound quickly. As explored in Biopharma Competitive Intelligence: Staying Ahead in Dynamic Markets, companies that maintain durable positioning treat CI as a continuous operating function — not a project triggered by a specific threat.
Why Underinvestment Happens Even at Sophisticated Companies
The underinvestment is rarely the result of ignorance. Most biopharma executives understand that CI matters. The structural reasons it gets deprioritized are more specific.
Resource allocation follows near-term milestones. In growth-stage companies, capital and management attention concentrate around the next clinical readout, the next regulatory submission, or the next fundraising round. CI investment that does not map to a 12-month deliverable is easy to defer. The problem is that the competitive events CI would have caught do not wait for convenient timing.
CI is hard to measure until the absence of it hurts. R&D spend produces data. Commercial spend produces revenue. CI spend produces awareness and optionality — outcomes that are difficult to quantify until a company misses a window and can trace the miss back to a specific intelligence gap. At that point, the cost is visible. Before that point, the investment looks discretionary.
The function is frequently mishoused. When CI sits inside medical affairs, it focuses on clinical data. When it sits inside commercial, it focuses on market share. Neither function has the mandate or cross-functional visibility to synthesize regulatory, payer, and BD signals simultaneously. The result is fragmented intelligence that serves individual teams without informing enterprise strategy.
The Moments When the Gap Becomes Visible
There are four situations where inadequate CI investment becomes a direct commercial problem.
BD&L negotiations. Valuation in a licensing or acquisition discussion is partly a function of competitive positioning. If your counterpart's CI team has a clearer picture of your competitive set than you do — who else is in the space, how far along they are, what payers have signaled about the category — they negotiate from an information advantage. That advantage gets priced into the deal.
Pipeline prioritization decisions. Committing capital to a development program without a current view of the competitive landscape is a material risk. A company that enters a phase III program without knowing two competitors are 18 months ahead in the same indication has made a resource allocation decision on incomplete information. The cost is not just the phase III spend — it is the opportunity cost of the programs that did not get funded.
Launch planning. Formulary access decisions are made 12 to 18 months before a product launches. PBMs and payers are watching the competitive pipeline during that window. If your commercial team is not watching it with the same rigor, you arrive at launch negotiations without the context to anticipate objections or structure access agreements effectively. The connection between CI gaps and commercial underperformance at launch is direct — and for biosimilar companies in particular, the consequences are severe, as detailed in Why Biosimilar Companies Are Leaving Money on the Table in Market Access.
Responding to patent cliff dynamics. The $300B+ patent cliff playing out through 2030 is not a single event — it is a rolling sequence of LOE windows, each reshaping competitive positioning in specific therapeutic areas. Companies that track these windows continuously can position assets, structure BD transactions, and engage payers ahead of the shift. Companies that track them reactively are always responding to a market that has already repriced. The strategic implications for growth-stage organizations are significant enough to warrant their own analysis, covered in depth in The Patent Cliff Is Real — What Growth-Stage Biopharma CEOs Should Do Now.
The Cost Is Not Just Financial
The financial cost of CI underinvestment is real — missed deal terms, suboptimal launch positioning, misdirected R&D capital. But the strategic cost is larger.
Companies operating without continuous CI make decisions reactively. They respond to competitor moves rather than anticipating them. They enter negotiations without the context to hold their position. They allocate pipeline resources based on assumptions that have not been stress-tested against current market data. Over time, that reactive posture compounds into a structural disadvantage — not just in individual transactions, but in how the organization is perceived by partners, acquirers, and investors.
Biopharma moves fast. Not "fast for a regulated industry" fast — genuinely fast. The compression of decision timelines across BD, regulatory, and commercial functions means a 60-day intelligence lag is not a minor inconvenience. It is a strategic exposure. The implications of that compression are examined in The Evolution of Biopharma Strategy: Why 60 Seconds Is the New 3 Weeks.
What Adequate CI Investment Actually Looks Like
Adequate CI is not a headcount question. It is a design question. The function needs to produce cross-functional synthesis — not siloed monitoring.
Practically, this means three things. First, CI must have a direct line to strategy — not filtered through commercial or medical affairs before it reaches the leadership team. Second, it must operate on a continuous cadence, not a quarterly reporting cycle; competitive events do not align with reporting calendars. Third, it must integrate external advisory input where internal bandwidth or expertise falls short — particularly in payer dynamics, regulatory signaling, and BD market intelligence, where pattern recognition built across many transactions is more valuable than any single company's internal data.
For growth-stage biopharma companies that lack the infrastructure to build this function internally, the practical path is sourcing it from advisors who have operated across enough transactions to distinguish signal from noise. Doug Drysdale's 35 years of hands-on biopharma leadership — including 17 acquisitions and more than $4 billion in capital raised — is the kind of pattern recognition that takes decades to build and cannot be replicated by a database subscription. That experience base is what Katogen brings to clients navigating CI gaps at critical inflection points.
Tools like Katogen Engine™ and Katogen Sentinel™ are built to close the speed gap: structured regulatory and issuer context for decisions, plus continuous watches that surface material catalysts before they show up in a quarterly deck.
The Window to Act Is Shorter Than You Think
Companies that get surprised by competitive moves are rarely the ones that lacked access to information. They are the ones that did not have a function capable of processing that information fast enough to act on it.
Building that function — or sourcing it externally — is a decision that needs to happen before the next competitive event, not after it. The cost of building CI capability is fixed and manageable. The cost of operating without it is variable and potentially existential.
If your organization is approaching a BD transaction, a product launch, or a pipeline prioritization decision without a current, cross-functional view of your competitive environment, that is the gap to close first. The strategic advisory work at katogen.com is built around exactly that kind of decision — translating operator experience into CI that is actionable, not just informative.
FAQs
What is biopharma competitive intelligence, and how does it differ from standard market research? Competitive intelligence in biopharma integrates pipeline tracking, regulatory signals, payer landscape dynamics, and BD&L activity into a continuous picture of competitive positioning. Standard market research tends to be point-in-time and category-focused. CI is ongoing, cross-functional, and oriented toward decisions — not just descriptions of the market.
Why do biopharma companies underinvest in CI even when they understand its value? The most common reasons are structural: resource allocation concentrates around near-term milestones, CI outcomes are difficult to quantify before a miss occurs, and the function is frequently mishoused within a single business unit that lacks cross-functional visibility. The investment looks discretionary until it isn't.
At what stage should a biopharma company build a formal CI function? Earlier than most companies act on it. By the time a company is in phase II development, competitive positioning is already influencing BD valuation, payer signaling, and pipeline prioritization. Companies that wait until commercial stage to build CI are already operating at an information disadvantage in negotiations and formulary access discussions.
How does CI underinvestment affect BD&L outcomes specifically? In BD&L negotiations, the party with better competitive intelligence holds a structural advantage. If a potential partner or acquirer has a clearer picture of your competitive set — including who else is in the space, how far along they are, and what payers have signaled — they can price that information into deal terms. Companies that enter these negotiations without current CI are negotiating against an information asymmetry.
What is the relationship between CI and launch performance? Formulary access decisions are made 12 to 18 months before launch. PBMs and payers are actively monitoring the competitive pipeline during that window. Companies tracking the same signals can anticipate payer objections, structure access agreements more effectively, and avoid being positioned reactively at launch. CI gaps at this stage translate directly into formulary exclusion risk and market access underperformance.
Can growth-stage companies build adequate CI without a large internal team? Yes, but it requires sourcing cross-functional pattern recognition externally where internal bandwidth is insufficient. The critical requirement is that CI has a direct line to leadership and operates continuously — not that it is built entirely in-house. Strategic advisory relationships with operators who have executed multiple transactions in relevant therapeutic areas can substitute for internal CI infrastructure at earlier stages.
How quickly does a CI gap become a material strategic problem? In a market where BD transactions close over weekends and formulary decisions are made months before launch, a 60-day intelligence lag is a material exposure — not a minor inconvenience. The compounding effect is significant: each reactive decision made without current CI narrows the options available for the next one. The gap becomes visible at a specific event, but the damage accumulates well before that moment.
For operator-led biopharma consulting on competitive intelligence, BD&L, and launch strategy, see our biopharma consulting services hub or contact Katogen.
